l e t t e r s nature medicine VOLUME 22 | NUMBER 12 | DECEMBER 2016 1 4 8 9 differentiation in the bone marrow ( Supplementary Fig. 1d ) and a modest increase in the myeloid bias ( Supplementary Fig. 1e ,f) of Dnmt3a mut mice. These data indicate that the expression of Dnmt3a mut in hematopoietic cells expands HSPCs and alters differentiation in vivo.
Although the majority of patients with acute myeloid leukemia (AML) initially respond to chemotherapy, many of them subsequently relapse, and the mechanistic basis for AML persistence following chemotherapy has not been determined. Recurrent somatic mutations in DNA methyltransferase 3A (DNMT3A), most frequently at arginine 882 (DNMT3A R882 ), have been observed in AML [1] [2] [3] and in individuals with clonal hematopoiesis in the absence of leukemic transformation 4, 5 . Patients with DNMT3A R882 AML have an inferior outcome when treated with standard-dose daunorubicin-based induction chemotherapy 6, 7 , suggesting that DNMT3A R882 cells persist and drive relapse 8 . We found that Dnmt3a mutations induced hematopoietic stem cell expansion, cooperated with mutations in the FMS-like tyrosine kinase 3 gene (Flt3 ITD ) and the nucleophosmin gene (Npm1 c ) to induce AML in vivo, and promoted resistance to anthracycline chemotherapy. In patients with AML, the presence of DNMT3A R882 mutations predicts minimal residual disease, underscoring their role in AML chemoresistance. DNMT3A R882 cells showed impaired nucleosome eviction and chromatin remodeling in response to anthracycline treatment, which resulted from attenuated recruitment of histone chaperone SPT-16 following anthracycline exposure. This defect led to an inability to sense and repair DNA torsional stress, which resulted in increased mutagenesis. Our findings identify a crucial role for DNMT3A R882 mutations in driving AML chemoresistance and highlight the importance of chromatin remodeling in response to cytotoxic chemotherapy.
Mutations in genes that regulate DNA and histone modifications are often observed in human cancers 9 , including AML 10 . Genetic studies of elderly subjects with clonal hematopoiesis and of functionally defined pre-leukemic clones have identified recurrent mutations in epigenetic regulators 4, 5, 8, 11, 12 , suggesting, together with studies in murine models [13] [14] [15] [16] , that these mutations increase hematopoietic stem/progenitor cell (HSPC) fitness and predispose them to subsequent malignant transformation. DNA methyltransferase 3A (DNMT3A) is the most commonly mutated epigenetic regulatory gene in AML 2, 3, 6 . Approximately half of all AML-associated DNMT3A mutations are monoallelic nonsense or frameshift alterations. Notably, almost half of all DNMT3A mutations occur at a single hotspot, arginine 882, which is mutated to histidine (R882H) or cysteine (R882C) 1, 17 . DNMT3A R882 mutations are the most prevalent somatic mutations observed in individuals with clonal hematopoiesis 4, 5 . Biochemical studies have suggested that DNMT3A R882 can function as a dominant-negative mutation with respect to methyltransferase activity [18] [19] [20] ; however, the role of these mutations in leukemia pathogenesis and in the response to anti-leukemic therapies has not been elucidated.
To address these questions, we generated a mouse model that conditionally expresses Dnmt3a R878H (mouse homolog to human DNMT3A R882H ) from the endogenous locus (Fig. 1a,b) . Polyinosinicpolycytidylic-acid treated Mx1-Cre;Dnmt3a R878H mice (Dnmt3a mut mice) expressed equal levels of Dnmt3a R878H and wild-type Dnmt3a mRNA species, resulting in physiologic protein expression (Fig. 1c) . Mice expressing Dnmt3a R878H in the absence of other disease alleles did not develop leukemia (Fig. 1d,h ), but were instead characterized by the accumulation of Lineage − Sca1 + cKit + (LSK) stem cell-enriched cells ( Fig. 1e and Supplementary Fig. 1a) and by an increased percentage of circulating c-Kit-positive progenitor cells (Fig. 1f) , consistent with HSPC expansion (Supplementary Fig. 1b) . Dnmt3a mut bone marrow cells exhibited enhanced serial colony-forming potential in vitro (Supplementary Fig. 1c) . We observed impaired erythroid DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling differentiation in the bone marrow (Supplementary Fig. 1d ) and a modest increase in the myeloid bias ( Supplementary Fig. 1e,f) of Dnmt3a mut mice. These data indicate that the expression of Dnmt3a mut in hematopoietic cells expands HSPCs and alters differentiation in vivo.
We hypothesized that expression of DNMT3A R882H would cooperate with other disease alleles to promote leukemic transformation. Analysis of AML data from The Cancer Genome Atlas (TCGA) and other sources 1,21 revealed a significant co-association of DNMT3A mutations with FLT3 internal tandem duplications (FLT3 ITD ) and nucleophosmin (NPM1) mutation causing its delocalization into the cytoplasm (NPM1 c ); notably, all three mutations were often concurrent (P < 1.9 × 10 −6 ; Fig. 1g ). Thus, we generated mice expressing Flt3 ITD , Dnmt3a mut and/or Npm1 c and assessed the ability of different combinatorial permutations to induce an AML phenotype (Fig. 1h) Fig. 1i and Supplementary Fig. 2a) , a hypercellular bone marrow with proliferating leukemic blasts, obliteration of splenic architecture and hepatic portal infiltration (Supplementary Fig. 2a) . We found that Dnmt3a mut contributed to leukemic transformation as a result of, at least in part, augmented stem cell function, as seen by enhanced competitive transplantability (Supplementary Fig. 2b,c) and elevated myeloid-to-lymphoid engraftment ratios in noncompetitive transplantation studies (Supplementary Fig. 2d) .
We next investigated the relevance of DNMT3A mutations to the response to anti-leukemic therapy. Previously, we showed that patients with mutated DNMT3A in the ECOG-ACRIN E1900 clinical trial had a poor outcome with standard-dose daunorubicin-based induction, consistent with other clinical studies [22] [23] [24] [25] ; however, the adverse prognostic effect of DNMT3A mutations was mitigated by daunorubicin dose intensification 6, 7 . These data suggest that DNMT3A mutations could promote resistance to anthracycline-based chemotherapy. We investigated whether mutations in DNMT3A or in other AML disease alleles are associated with the presence or absence of flow-cytometrically defined minimal residual disease (MRD) after induction chemotherapy in the ECOG-ACRIN E1900 clinical trial cohort (Fig. 2a) Scale bar represents 50 µm; images are representative of at least five random fields. *P < 0.05; ***P < 0.001; ****P < 0.0001.
prognostic value in AML [26] [27] [28] [29] [30] . In a multivariate analysis, DNMT3A R882 mutations, but not non-R882 DNMT3A mutations or mutations in other AML genes, robustly predicted the presence of MRD following induction chemotherapy (P = 0.007; Fig. 2b and Supplementary Table 1) .
We next performed mutational analysis on nine paired samples (from diagnosis and 28 d post-induction) from our E1900 AML cohort with DNMT3A R882 mutations and MRD analysis by flow cytometry. In eight of the nine cases, mutational studies revealed that the R882 mutant disease allele was present at a detectable variant allele frequency at the time of clinical remission (average sequencing depth of 2,246×). In cases with flow-positive MRD, we found that the small leukemic clone (DNMT3A and other mutations) was overlaid on a larger (majority of the cells) DNMT3A-mutant pre-leukemic population or a persisting bulk DNMT3A-mutant pre-leukemic population; in both scenarios, we observed subsequent relapse. A persisting DNMT3A-mutant pre-leukemic subpopulation was detected in MRDnegative cases ( Supplementary Fig. 3a and Supplementary Table 2 ). These data indicate that DNMT3A R882 mutations are associated with AML chemoresistance and with the persistence of leukemic and preleukemic DNMT3A R882 mutant cells following chemotherapy.
AML cell lines (OCI/AML-3 and SET-2) with DNMT3A R882 mutations were less sensitive to daunorubicin than non-R882 DNMT3A mutant (OCI/AML-2) and DNMT3A wild-type (MOLM-13 and MV4:11) AML cells ( Fig. 2c and Supplementary Fig. 3b ). By contrast, DNMT3A mutational status did not influence the sensitivity of AML cells to DNA-damaging agents with other mechanisms of action, including bleomycin and mitomycin C (Fig. 2d,e) . Expression of DNMT3A R882H reduced MOLM-13 cells' sensitivity to daunorubicin ( Supplementary Fig. 3c ), and Dnmt3a mut mouse embryonic fibroblasts (MEFs) showed reduced sensitivity to daunorubicin, but not to other DNA-damaging agents in vitro ( Fig. 2f-h ). We found decreased sensitivity to anthracyclines (daunorubicin and doxorubicin) in Dnmt3a mut bone marrow that was plated in methylcellulose ( Fig. 2i) , which was enhanced with serial passage. In vivo studies with doxorubicin revealed an enrichment of immature LSK cells in the bone marrow of Dnmt3a mut -engrafted mice that translated into enhanced colony-forming potential ex vivo (Fig. 2j,k) . Anthracycline treatment of recipient mice engrafted with wild-type bone marrow reduced quiescence and increased short-term hematopoietic stem cell (HSC) numbers at the expense of long-term HSC in vivo, which we did not observe in mice engrafted with bone marrow from Dnmt3a mut mice ( Supplementary Fig. 3d,e) . We next performed studies in primary AML samples with FLT3 ITD and NPM1 c mutations, and found that samples harboring DNMT3A mutations showed reduced sensitivity to anthracyclines ex vivo compared with wild-type samples (Fig. 2l) , although the difference vanished at higher concentrations (data not shown).
The modest DNA hypomethylation relative to other AML alleles with altered DNA methylation 31 , as assessed by enhanced reduced representation bisulfite sequencing (ERRBS) 32, 33 (Supplementary Tables 3  and 4) ; the paucity of genes with expression changes (Supplementary Table 5 ) correlating with changes in DNA methylation; and the lack of enrichment of pathways relevant to cell survival or drug metabolism in mouse Dnmt3a mut LSK cells compared with wild-type controls suggest that alterations in DNA methylation at specific loci are unlikely to explain anthracycline resistance in DNMT3A R882 mutant cells ( Supplementary Fig. 3f-h ). Anthracycline resistance was not a result of differential drug efflux, metabolism or intracellular compartmentalization of anthracyclines ( Supplementary Fig. 4a-f ). These data suggest a mechanism for anthracycline chemoresistance in AML cells with DNMT3A R882 mutations. We next investigated whether DNMT3A R882 mutant cells have an intact DNA damage response (DDR) to anthracyclines. Daunorubicin induces DNA torsional stress at lower doses and can inhibit topoisomerase II, leading to double-strand breaks at higher concentrations 34 . DNMT3A mutant AML cells showed attenuated CHK1 phosphorylation and downstream signaling, including reduced phosphorylated histone H2A.X (γH2A.X), p53 phosphorylation and stabilization, and apoptotic signaling (cleaved PARP and caspase 3) in response to daunorubicin, as compared to wild-type cells (Fig. 3a,b) . CHK2 activation remained intact, suggesting the presence of a defect in the ATR/CHK1 pathway that was specific to daunorubicin and not etoposide, a DNA-topoisomerase II inhibitor ( Supplementary  Fig. 5a ). Expression of DNMT3A R882C/H , but not wild-type DNMT3A, in AML cells modestly attenuated the p53 response (Fig. 3a,b and Supplementary Fig. 5b ) and γH2A.X accumulation in AML cells and in Dnmt3a mut mice after anthracycline exposure (Fig. 3a,b and Supplementary Fig. 5c,d) . Gene expression analysis of Dnmt3a mut LSK cells revealed negative enrichment of the Chk1-regulated G2/M checkpoint signature 35 ; the same signature was also significantly attenuated in DNMT3A R882 primary AML samples from the TCGA data set (Fig. 3c) . The defect in checkpoint activation was not seen in Dnmt3a haplo-insufficient LSKs or in patients with AML with DNMT3A mutations other than DNMT3A R882 (Supplementary Fig. 5e) .
We next investigated possible changes in the DNA state leading to the DDR signaling defect after daunorubicin treatment in DNMT3A R882 cells using a comet assay, which reads out DNA single-and double-stranded breaks and other conditions leading to relaxation of DNA supercoiling, such as the presence of labile apurinic sites or changes in nucleosomal density 36 . DNMT3A R882 -transduced cells had an increased alkaline comet signal in response to daunorubicin (Fig. 3d) , which we also observed in TP53 mutant AML cells (Supplementary Fig. 5f ). We found a similar increase in comet signal in primary FACS-sorted multipotent progenitors from Dnmt3a mut bone marrow, compared with wild-type controls (Supplementary Fig. 5g) , and in primary AML patient samples harboring DNMT3A R882 mutations as compared to wild-type AML cells (Fig. 3e) . DNMT3A non-R882 mutant cells showed a variable response to daunorubicin in the comet assay, suggesting that other, less common DNMT3A mutations might have a differential response to anthracyclines. Expression of DNMT3A R882 , but not wild-type DNMT3A, increased the rate of secondary mutations, as measured by the number of 6-thioguanine-resistant HPRT-mutant colonies in hematopoietic and non hematopoietic cells ( Fig. 3f and Supplementary Fig. 5h ), which might be explained by inadequate repair of increased DNA damage as a result of impaired signaling. Taken together, these data suggest that DNMT3A R882 cells fail to initiate CHK1-mediated DDR after anthracycline treatment.
We noted that DNMT3A R882 cells showed reduced sensitivity to aclarubicin, but not to etoposide ( Fig. 4a and Supplementary  Fig. 6a,b) . Given that aclarubicin induces torsional stress and that etoposide inhibits topoisomerase II, whereas daunorubicin acts through both mechanisms, these data suggest a specific mechanism of resistance to DNA damage. Previous studies have shown that torsional stress imposed by anthracyclines destabilizes nucleosomes, which facilitates remodeling and histone eviction as the first step immediately after topological DNA strain, contributing to cytotoxicity 34, 37 . We evaluated whether DNMT3A R882 cells have impaired chromatin remodeling and reduced histone eviction in response to anthracyclines. Daunorubicin induced significant histone eviction and an increase in free nuclear histones in wild-type AML cells, , non-R882 mutations (gray, OCI/AML-2) or no mutations (black, MOLM-13 and MV4:11) relative to untreated control (*P < 0.05, all pairwise comparisons between DNMT3A wild-type and mutant cell lines). Data are representative of at least three independent experiments. (f-h) Sensitivity to daunorubicin (f), bleomycin (g) and mitomycin C (h) in immortalized MEFs derived from Dnmt3a mut (MUT) and wild-type (WT) animals, relative to untreated control, representative of two replicate experiments (**P < 0.01, ****P < 0.0001). (i) Clonogenic survival in MethoCult M3434 of bone marrow cells derived from three Dnmt3a mut and three WT mice in duplicate after ex vivo exposure to daunorubicin at first plating. Shown are the number of colonies relative to untreated control (*P < 0.05, **P < 0.01). (j,k) Fraction of LSK cells in Lineage − population (j) and clonogenic potential (number of colonies per 10 4 unfractionated cells plated in MethoCult M3434 in triplicate) of bone marrow cells (k) derived from Dnmt3a mut and wild-type mice after a one-time in vivo exposure to 3 mg/kg doxorubicin (n = 3-4, *P < 0.05). Recipient mice were engrafted with whole bone marrow derived from young newly recombined Dnmt3a mut or WT control congenic donors and allowed 3 months to reconstitute steady-state hematopoiesis, at which point they were treated with a single dose of doxorubicin (3 mg/kg) or vehicle and analyzed 24 h later. Data are representative of two independent transplant experiments. (l) Ex vivo sensitivity to anthracyclines daunorubicin (left) and doxorubicin (right) at indicated concentrations in nine primary FLT3 ITD NPM1 c AML samples depending on their DNMT3A status (black, DNMT3A WT, n = 5; red, DNMT3A mutant, n = 4; *P < 0.05, # P = 0.06, t test with Welch's correction). Detection of all types of DNA breaks and changes in DNA looping by alkaline comet assay in MOLM-13 cells retrovirally transduced with DNMT3A R882H , wild-type or empty vector control after 16 h of daunorubicin (25 ng/ml) exposure in vitro (**P < 0.01, ****P < 0.0001, Mann-Whitney rank-sum test). (e) Alkaline comet assay in a panel of primary AML samples with different DNMT3A mutational status (black, no mutations; red, R882 mutations; gray, other non-R882 mutations) after 16 h exposure to daunorubicin (25 ng/ml) in vitro (****P < 0.0001, Mann-Whitney rank-sum test). Sample #208 with DNMT3A V778E substitution seemed to be more similar to wild-type samples (P = 0.2310), whereas AML sample #278 with a truncating Q420* mutation was more similar to DNMT3A R882 cases (P = 0.4003). (f) Random mutagenesis measured by number of 6-TG-resistant colonies in 293T cells retrovirally transduced with DNMT3A R882H , wild-type or empty vector control (*P < 0.05, **P < 0.01, ***P < 0.001). Data are representative of at least three independent biological replicates.
which were markedly attenuated in DNMT3A R882H cells (Fig. 4b) . A similar defect in histone eviction was observed in Dnmt3a mut MEFs (Supplementary Fig. 6c ) and in hematopoietic cells from Dnmt3a mut mice (Fig. 4c) . This mechanism was specific to anthracycline treatment, as we observed no difference in histone release after etoposide treatment in cells expressing wild-type or mutant forms of DNMT3A (Supplementary Fig. 6d) .
We next sought to identify the specific proteins involved in the impaired nucleosome turnover and histone eviction in DNMT3A R882 cells. Protein pull-down assays in cell nuclear extracts using a synthetic peptide corresponding to DNMT3A N-terminal domain, followed by mass spectroscopy (Supplementary Table 6) , identified the facilitates chromatin transcription (FACT) complex subunit SPT-16, which is a histone H2A/H2B dimer chaperone that is also involved in DNA replication and repair [38] [39] [40] , encoded by the SUPT16H gene. We validated this interaction using co-immunoprecipitation studies in cells expressing endogenous and ectopic levels of DNMT3A (Fig. 4d and  Supplementary Fig. 7a,b) . Reciprocal co-immunoprecipitation experiments confirmed direct protein-protein binding between DNMT3A and SPT-16 ( Supplementary Fig. 7c,d) . We observed daunorubicininduced SPT-16 recruitment to chromatin in cells expressing wildtype DNMT3A, which was attenuated by expression of DNMT3A R882 (Fig. 4e) . Consistently with these data, shRNA-mediated knockdown of SUPT16H decreased the sensitivity of cells to aclarubicin, similar Figure 4 Expression of mutant DNMT3A impairs chromatin remodeling in response to DNA distortion. (a) Sensitivity to aclarubicin (torsional stress) and etoposide (topoisomerase II inhibition) in leukemia cell lines with different DNMT3A mutational status (red, R882 mutations; black, no mutation; ***P < 0.001, ****P < 0.0001, pair-wise comparisons between DNMT3A wild-type and mutant cell lines). (b) Distribution of histones H2A and H3 and of DNA single-strand-binding protein RPA between chromatin-bound fraction and soluble nuclear extract after in vitro daunorubicin treatment in a panel of cell lines with different DNMT3A status synchronized in early S-phase by double thymidine block (red, R882 mutation; gray, non-R882 mutation; black, no mutation). Protein abundance in each of the cellular compartments was analyzed by western blotting. (c) Distribution of histone H2A between chromatin-bound fraction and soluble nuclear extract after 4 h of daunorubicin treatment in splenocytes derived from Dnmt3a mut , wild-type, and haplo-insufficient animals. (d) Co-immunoprecipitation with Dnmt3a-specific antibodies using nuclease-treated extracts from MEF cells expressing either one wild-type copy of Dnmt3a (+/−) or one mutant copy of Dnmt3a (−/m), analyzed for the presence of endogenous Dnmt3a and Spt-16 by western blotting. Cells were exposed to 250 ng/ml daunorubicin for 4 h before harvest where indicated. (e) Distribution between chromatin-bound and free nuclear states of SPT-16 and of DNA helicase TFIIH in 32D cells retrovirally transduced with DNMT3A R882 , wild-type or empty vector control after 4 h of treatment with 250 ng/ml daunorubicin. to effects seen in DNMT3A mutant cells (Fig. 4f) , and abrogated the effect of wild-type DNMT3A on histone eviction after daunorubicin (Fig. 4g) . Of note, both wild-type and mutant DNMT3A were able to bind SPT-16, suggesting a defect in the ability of DNMT3A R882 to bind DNA and recruit SPT-16 to nucleosomes. Chromatin immunoprecipitation sequencing (ChIP-seq) analysis in MEFs expressing either wild-type or mutant Dnmt3a, but not both, revealed a marked reduction in DNA binding by the Dnmt3a mutant compared with wild-type or haplo-insufficient cells (Supplementary Fig. 7e,f) .
Our findings show that leukemia-associated DNMT3A R882 mutations promote HSC function and cooperate with FLT3 ITD and NPM1 c mutations to induce AML. DNMT3A R882H AML cells showed increased resistance to anthracycline-based chemotherapy, which results from a proximal defect in nucleosome remodeling that attenuates DDR (Supplementary Fig. 7g) . Our data describe a previously unknown mechanism of chemoresistance in AML that is driven by a specific mutation in an epigenetic regulator, and provide insights that can be used to interrogate DNA damage pathways as a therapeutic vulnerability in this common, poor-risk AML subtype.
MeThODS
Methods and any associated references are available in the online version of the paper.
Accession codes. RNA-seq, ERRBS, and ChIP-seq raw and processed data were deposited into GEO database under bundle ID GSE72883 (RNA-seq: GSE72737; ERRBS: GSE86827; ChIP-seq: GSE72882). 
ONLINe MeThODS
Generation of the conditional Dnmt3a R878H allele in mice. To achieve inducible expression of the Dnmt3a R878H allele from its endogenous locus, a minigene combining exons 23 and 24 carrying a point mutation was inserted in place of endogenous Dnmt3a exon 23, preceded by a Lox-Stop-Lox Neo R (LSL) cassette (Fig. 1a) . After selection on G418, targeted mouse ES cell clones were screened by PCR and verified by Southern blotting; positive clones were expanded and injected into blastocysts. Removal of the stop cassette by Cremediated excision allows for the expression of the mutant Dntm3a R878H mRNA and protein, confirmed by Sanger sequencing of the cDNA derived from peripheral blood mononuclear cell RNA.
Animals, bone marrow transplantation and flow-cytometric analysis. Laboratory mice were housed at the Memorial Sloan Kettering Cancer Center animal facility; all animal procedures were approved by the Institutional Animal Care and Use Committee. To achieve inducible hematopoietic-specific excision, Dnmt3a +/LSL-R878H animals crossed to Mx1-Credeletor received four intraperitoneal injections of poly(I:C) (Amersham). For phenotyping of primary animals, nine Dnmt3a +/+ ;Mx1-Cre + , 12 Dnmt3a +/LSL-R878H ;Mx1-Cre + and eight Dnmt3a +/LSL-R878H ;Mx1-Cre − were used. The number of animals was chosen to ensure 90% power with 5% error based on observed s.d. For re-transplantation and bone marrow engraftment studies, 1 × 10 6 mononuclear cells from freshly harvested bone marrow were injected through tail veins into lethally irradiated (9.5 Gy) CD45.1 recipients; Mx1-Cre-driven recombination was induced by poly(I:C) injections in the recipients and was confirmed by Sanger sequencing of cDNA generated from peripheral blood mononuclear cells. For competitive bone marrow transplantation studies, 1 × 10 6 CD45.2 test bone marrow cells were competed against an equal number of CD45.1 wild-type cells and monitored by CD45.1/CD45.2 peripheral blood chimerism every 2 months; Mx1-Cre-driven recombination was induced by poly(I:C) injections in the recipients and was confirmed by Sanger sequencing of cDNA generated from peripheral blood mononuclear cells. Animals that failed to engraft (<1% CD45.2 chimerism in peripheral blood) or were lost due to poly(I:C) toxicity were excluded from analysis. For in vivo Dox treatment studies, lethally irradiated CD45.1 recipients were engrafted with 1 × 10 6 CD45.2 test bone marrow cells recombined in the donor; randomization was done by conducting CBC analysis before the start of drug administration and confirming that WBC count averages were equivalent in treatment and vehicle groups. Blinding was not done in these experiments. Peripheral blood was collected by submandibular puncture. Complete blood counts were obtained using IDEXX ProCyte DX automated hemocytometer. Flow cytometric analysis of mature blood lineages was performed as described 41 . Analysis of the hematopoietic stem and myeloid progenitor populations was performed on singlecell suspensions prepared from bone marrow, spleens and livers by flow cytometry after red blood cell lysis. Populations were defined as follows . For immunophenotypic analysis of erythroid maturation the red blood cell lysis step was omitted; erythroblastic progenitor populations were defined as described 43, 44 . All antibodies were from eBioscience or BioLegend: NK1.1 (PK136), CD11b (M1/70), CD45R (RA3-6B2), CD3 (17A2), Gr-1 (RB6-8C5), Ter119 (TER119), CD19 (6D5), CD4 (GK1.5), CD8 (53-6.7), cKit (2B8), Sca-1 (D7), CD150 (TC15-12F12.2), CD48 (HM48-1), CD16/32 (93), CD34 (RAM34), CD71 (R17217), Ki67 (SolA15), CD45.1 (A20), CD45.2 (104). Cell viability was monitored by propidium-iodide (PI) exclusion, DNA content was measured in formaldehyde-fixed and Triton X-100 permeabilized cells by DAPI staining. Peripheral blood smears were stained using the Wright-Giemsa method. For histological analysis spleens, livers and sterna were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H/E). Slides were scanned using PerkinElmer Panoramic FLASH scanner and a CIS VCC color CCD camera.
Clonogenic potential in semisolid media. Freshly isolated 1 × 10 4 whole bone marrow cells were plated in MethoCult M3434 medium (StemCell) containing daunorubicin where indicated, in duplicate or triplicate. Colonies were counted after 10-14 d, when cells were harvested and replated, 1 × 10 4 cells per well in replicate, for an indicated number of passages or until colony-forming potential was exhausted.
Minimal residual disease in patients with AML. Patient samples were obtained from the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) and from the Memorial Sloan Kettering Cancer Center; IRB approval was obtained from the MSKCC Institutional Review Board; all patients provided informed consent. Presence of minimal residual disease was assessed centrally in the ECOG-ACRIN Leukemia Translational Research Laboratory (LTRL) on day 28 after induction chemotherapy by multi-parameter flow cytometry using a FACSCanto II cytometer operated with FACSDiva software for both acquisition and analysis. Given the substantially lower MRD levels in blood than bone marrow in AML 45 , submission of aspirates was requested at all MRD time-points. Residual leukemic cells were identified on the basis of leukemiaassociated immunophenotypic features found at diagnosis.
Heparinized bone marrow aspirates were shipped to the LTRL by overnight delivery on cool-packs and processed within 24 h of collection. MRD was determined in whole, unseparated samples and expressed as the percentage of nucleated white blood cells based on SYTO 16 green fluorescent nucleic acid staining (Invitrogen). Antibody panels for MRD determination were based on the findings at diagnosis. If more than one immunophenotypic clone was detected at diagnosis, antibody panels for MRD assessment were adjusted accordingly to cover all the antigen combinations of interest. Whenever possible, a minimum of 200,000 events were acquired. To reach this goal, aspirates with very low white blood cell count were subjected to red cell lysis with a solution of ammonium chloride, potassium bicarbonate and EDTA at room temperature for 10 min. In agreement with the literature, the threshold for MRD positivity was set at ≥0.1% of cells, which stained for leukemiaassociated features 46 .
Molecular persistence of DNMT3A-mutant clones and other AML-associated mutations 28 d after induction was assessed by hybridization capture-based next-generation sequencing of patient DNA purified from PBMCs for alterations included in the MSKCC-IMPACT panel, as previously described 47 . The average sequencing depth was 2,246× to ensure that even the lowest covered regions in the panel are covered at >500×. See also Supplementary Table 2.
MEFs. MEFs were generated from E13.5 embryos by trypsin dissociation after the removal of neural and fetal liver tissues. Fibroblasts were grown in DME supplemented with 4.5 g/l glucose, nonessential aminoacids (Gibco), 10% FCS (FCS), and penicillin/streptomycin and immortalized by SV40 large T-antigen by direct transfection. Expression of the Dnmt3a R878H allele was achieved by lentivirally mediated expression of the Cre recombinase. For generation of MEFs that only expressed wild-type Dnmt3a or Dnmt3a R878H allele, but not both, Dnmt3a +/LSL-R878H animals were crossed with Dnmt3a f/f conditional knockout line 48 . Complete excision and expression of the Dnmt3a R878H allele was verified by cDNA Sanger sequencing.
Cell lines. Cell line authentication by STR (short tandem repeat) profiling was performed at Genetica DNA Laboratories, LabCorp. Cell line identity was confirmed at 100% except OCI/AML-3 and SET-2, which showed minor genetic drift within acceptable range (94.1% and 96.3% match, respectively). MOLM-13 cells were authenticated by a collaborator. KO-52 line was recently procured from a cell repository, therefore testing was not performed. Prior to experimental work, all cell lines were maintained on 50 µg/ml plasmocin (InvivoGen) over the course of 3 weeks for mycoplasma prevention. Mycoplasma testing was performed using a PCR-based kit according to manufacturer's instructions (Applied Biological Materials). DNMT3A R882 mutant status was validated by Sanger sequencing of DNMT3A exon 23 on genomic DNA. Human leukemia cell lines were grown in RPMI supplemented with 10-20% FCS and penicillin/streptomycin. 293T cells were maintained in DME with 10% FCS and penicillin/streptomycin.
